Related Experiment Video
Updated: Oct 13, 2025
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene
Arianna Venturini1, Anna Borrelli1, Ilaria Musante2,3
1Telethon Institute of Genetics and Medicine (TIGEM), 80078 Pozzuoli, Italy.
Abstract:
Cystic fibrosis (CF) is caused by loss of function of the CFTR chloride channel. A substantial number of CF patients carry nonsense mutations in the CFTR gene. These patients cannot directly benefit from pharmacological correctors and potentiators that have been developed for other types of CFTR mutations. We evaluated the efficacy of combinations of drugs targeting at various levels the effects of nonsense mutations: SMG1i to protect CFTR mRNA from nonsense-mediated decay (NMD), G418 and ELX-02 for readthrough, VX-809 and VX-445 to promote protein maturation and function, PTI-428 to enhance CFTR protein synthesis. We found that the extent of rescue and sensitivity to the various agents is largely dependent on the type of mutation, with W1282X and R553X being the mutations most and least sensitive to pharmacological treatments, respectively. In particular, W1282X-CFTR was highly responsive to NMD suppression by SMG1i but also required treatment with VX-445 corrector to show function. In contrast, G542X-CFTR required treatment with readthrough agents and VX-809. Importantly, we never found cooperativity between the NMD inhibitor and readthrough compounds. Our results indicate that treatment of CF patients with nonsense mutations requires a precision medicine approach with the design of specific drug combinations for each mutation.
Insights
Treating cystic fibrosis (CF) nonsense mutations requires personalized drug combinations. Different CFTR mutations respond uniquely to therapies targeting mRNA decay, readthrough, and protein function.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Cystic fibrosis (CF) is a genetic disorder caused by dysfunctional CFTR protein.
- Nonsense mutations in the CFTR gene lead to premature stop codons, preventing functional protein production.
- Current CFTR-targeting drugs are ineffective for patients with nonsense mutations.
Purpose of the Study:
- To evaluate combination therapies for CFTR nonsense mutations.
- To identify effective drug combinations targeting various molecular levels.
- To determine mutation-specific drug responses.
Main Methods:
- Testing drug combinations including SMG1i (NMD inhibition), G418/ELX-02 (readthrough), VX-809/VX-445 (maturation), and PTI-428 (synthesis).
- Assessing CFTR rescue and function for W1282X, R553X, and G542X mutations.
- Analyzing drug efficacy and potential cooperativity.
Main Results:
- Drug response varied significantly based on the specific CFTR nonsense mutation.
- W1282X-CFTR showed high sensitivity to NMD suppression (SMG1i) and correction (VX-445).
- G542X-CFTR required readthrough agents and VX-809; no cooperativity was observed between NMD inhibitors and readthrough compounds.
Conclusions:
- CF treatment for nonsense mutations necessitates a precision medicine strategy.
- Tailored drug combinations are crucial for optimizing therapeutic outcomes.
- Understanding mutation-specific responses is key to developing effective CF therapies.
Related Concept Videos
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
01:59CRISPR